News Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
11.8 ^USD	-1.01%		-6.20%	+45.14%

Mar. 29	General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	CI
Mar. 14	Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election	Mar. 29	CI
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	Mar. 25	AQ
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	Mar. 22	AQ
Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating	Mar. 14	MT
Transcript : Iovance Biotherapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:45 AM	Mar. 12
Iovance Biotherapeutics to Present at Upcoming Conferences	Mar. 04	AQ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	Mar. 04	MT
Iovance Biotherapeutics Says FDA Lifts Partial Clinical Hold on Lung Cancer Study	Mar. 04	MT
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145	Mar. 04	DJ
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer	Mar. 04	AQ
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer	Mar. 04	CI
Iovance Biotherapeutics to Present at Upcoming Conferences	Mar. 01	AQ
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $25 From $22, Maintains Overweight Rating	Mar. 01	MT
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	Feb. 29	AQ
Barclays Raises Price Target on Iovance Biotherapeutics to $22 From $18, Maintains Overweight Rating	Feb. 29	MT
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue	Feb. 29	MT
Iovance Biotherapeutics: Q4 Earnings Snapshot	Feb. 28	AQ
Transcript : Iovance Biotherapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Reports Q4 Revenue $482,000	Feb. 28	MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Iovance Biotherapeutics, Inc.

Equities

IOVA

US4622601007

Summary

Filters